恒瑞医药盘中涨超3% Myosin抑制剂HRS-1893实现海外授权-港股-金融界

Core Insights - Heng Rui Medicine (01276) saw its stock price increase by 2.89% to HKD 83.70, with a trading volume of HKD 162 million [1] Group 1: Business Development - Heng Rui Medicine announced an exclusive licensing agreement with BraveheartBio for its self-developed Myosin small molecule inhibitor HRS-1893 [1] - The business development (BD) transaction operates under a NewCo model, contributing to a total of over USD 15 billion in BD transactions for Heng Rui Medicine this year [1] - The agreement grants BraveheartBio exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1]